Roy Martin, Jr.
Roy Martin, Jr. (Medical Device News Magazine)

Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, today announced that veteran board member Mr. Roy Martin Jr. has been named Executive Chairman of the Board.  Mr. Martin is an experienced leader with a demonstrated history of delivering results in the healthcare, legal, tax, scientific and SaaS software industries.  He has served as the Chairman of the Board for Pursuit Vascular since 2012.

“I’m happy to join the Pursuit Vascular leadership team in bringing solutions to dialysis providers and patients that will reduce and prevent catheter-related infections and associated illness and death in the US and worldwide,” Martin said of his appointment.  “I look forward to guiding the expansion of the ClearGuard HD Antimicrobial Caps in the global hemodialysis market as well as building on this foundation to develop additional solutions for other catheter-related therapies.”

Following a distinguished career as a senior executive in global information businesses, Mr. Martin founded WELM Ventures, a venture capital firm, in 2011, and remains CEO.  WELM invests in early stage companies specializing in medical device, information technology and digital media.  Mr. Martin was a long-time senior executive and one of 5 division CEOs at Thomas Reuters, a global information business in the legal, tax, financial and scientific markets, and helped lead Truven Health Analytics to its successful acquisition by IBM Watson Health in 2016.

In May, the FDA cleared the company’s ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with catheters based on real-world evidence.  Earlier this year, the results from another major study conducted by DaVita Clinical Research were published in the Journal of American Society of Nephrology (JASN).  Last year, findings from a study conducted by researchers at Fresenius Medical Care were published in the American Journal of Kidney Diseases (AJKD).  Both studies demonstrated a significant reduction in bloodstream infections of ~70% over currently used caps and connectors.

“Pursuit Vascular is at an inflection point after publication of multiple well designed, prospective, randomized controlled trials with astounding results featured in two major journals,” said Doug Killion, President & CEO.  “Roy is a great addition to our team and his proven record of success scaling technologies worldwide will be a tremendous asset.”

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here